DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and Operational Progress
Retrieved on:
Tuesday, September 21, 2021
Patent, EUR, Therapy, EDT, Simcere Pharmaceutical, National Institute on Aging, CEST, Partnership, VIVA, Greater, Amyloid, National, ADCS, NIA, Alzheimer's Research & Therapy, Board of directors, Conference, Arthur Andersen, Patient, Cancer, European, Tata Business Support Services, Q&A, MCI, CEO, Company, University, Annual general meeting, K, Alzheimer's Disease Cooperative Study, De Vijverberg, Euronext Amsterdam, University Medical Center, COVID-19, National Institute, Research, NIH, Safety, QPCT, Ernst & Young, Conference call, Protein, Director, Flour, Pharmaceutical industry, Lithium, Broadcasting
"In the first half of 2021, we made significant progress towards bringing our lead candidate varoglutamstat to patients suffering from Alzheimer's disease.
Key Points:
- "In the first half of 2021, we made significant progress towards bringing our lead candidate varoglutamstat to patients suffering from Alzheimer's disease.
- In the first two quarters of 2021, research and development expenses amounted to EUR 9,456 k (H1 2020: EUR 6,380 k).
- This increase was mainly driven by higher expenses for production (H1 2021: EUR 4,194 k, H1 2020: EUR 1,876 k), expenses for share-based payments (H1 2021: EUR 464 k, H1 2020: EUR 3 k) and higher costs associated with basic research projects in connection with Meprin (H1 2021: EUR 220 k, H1 2020: nil) and cancer (H1 2021: EUR 162 k, H1 2020: nil).
- This increase is largely attributable to costs for consulting (H1 2021: EUR 1,030 k, H1 2020: EUR 481 k) and expenses for share based payments (2021: EUR 464 k, 2020: nil).